NFKB1 and inflammatory bowel disease: Based on the pathways outlined in Figure 2, this section of the review will specifically focus on three pharmacological targets for IBD: (1) inhibition of SK, (2) inhibiting specific catalytic subunits of the immunoproteasome, and (3) modulating NF-κB/STAT3 interactions.